Cue Biopharma downsizes to focus on autoimmune pipeline

Cue Biopharma has instituted strategic restructuring measures with a plan to focus on autoimmune programs and carry out a workforce reduction.

The company plans to fire 25% of its staff, which along with other cash reduction measures is expected to save Cue Biopharma $30m in operating expenses in 2025. The company added that following the restructuring its cash runway will extend to mid-2025.